Podcasts

Episode 24 | The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations

A/Prof Melissa Moore is joined by Dr Katharine See and Dr Naveed Alam to discuss and review the findings and implications for NSCLC patients.

The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations

Episode Summary

In this Podcast, we discuss early NSCLC management and treatment, particularly in light of how immunotherapy will impact surgical and respiratory medicine as the landscape evolves with new data. A/Prof Melissa Moore is joined by Dr Katharine See and Dr Naveed Alam to discuss and review the findings and implications for NSCLC patients.

 

Thank you to Roche for collaborating on this podcast.

Show Hosts

This episode’s host are:

  • A/Prof Melissa Moore, Educational Chair, TOGA; Medical Oncologist
  • Dr Katharine See, Director and Head of Respiratory Medicine, Northern Hospital, Melbourne
  • Dr Naveed Alam, Thoracic Surgeon, St Vincent’s Hospital and Epworth

 

Play Episode 24 | The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations

More Podcasts

A conversation with Associate Professor Tom John and Professor Ben Solomon where they discuss the increased survival benefits for patients with oncogene driven lung cancer
In this Podcast, Mark Scott talks with Alexandra Golledge about her challenges in diagnosis, searching for the best treatments available, living in a regional area
Prof Nick Pavlakis and Prof Emily Stone join discuss the remarkable advances in screening, diagnosing and treating lung cancer that occurred during 2020.
Dorothy Keefe, CEO of Cancer Australia and Mark Scott discuss the COVID impact on diagnosing and treating lung cancer patients.
A fireside chat with Prunella Blinman, Shankar Siva and our three Preceptees: Anna Lawless, Abhijit Pal and Melanie Rabbets about their experiences, their learnings, what
In this episode, Prof Anna Nowak and A/Prof Steven Kao discuss the emerging treatments for mesothelioma patients and the DREAM3R trial.